Monday, August 3, 2020
Havana.- The health system in the eastern Cuban province of Camagüey resumed the use of HeberFERON, a medicine used against basal cell skin cancer.
The drug is administered at the Madame Curie Oncology and the Amalia Simoni Surgical Clinical hospitals.
Produced at the Genetic Engineering and Biotechnology Center (CIGB) in Havana, the drug has benefited 45 people in the territory.
The province shows favorable results with its administration, achieving approximately 74.5 percent of complete response to treatment in 2018 and 93.8 percent in 2019.
From 2017 to the end of last year, 136 therapeutic indications of mutilation of the nose and any of its areas, ears and eyes, on the eyelids and internal and external angles of the latter were prevented, thanks to the medication.